-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

Benzinga·08/12/2026 16:06:53
Listen to the news
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.